SY-640 is an acetamide analogue with effective hepatoprotective effects. SY-640 attenuates Propionibacterium acnes- and lipopolysaccharide-induced liver injury in mice.

Physicochemical Properties

Molecular Formula	C11H13NO3
Molecular Weight	207.23
Exact Mass	207.089
CAS #	168705-70-2
PubChem CID	9837165
Appearance	Light yellow to yellow liquid
Density	1.2±0.1 g/cm3
Boiling Point	349.2±21.0 °C at 760 mmHg
Flash Point	165.0±22.1 °C
Vapour Pressure	0.0±0.8 mmHg at 25°C
Index of Refraction	1.557
LogP	0.89
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	2
Heavy Atom Count	15
Complexity	244
Defined Atom Stereocenter Count	0
SMILES	C(N(CC1=CC=C2OCOC2=C1)C)(=O)C
InChi Key	JIWDGIYBLGMPRV-UHFFFAOYSA-N
InChi Code	InChI=1S/C11H13NO3/c1-8(13)12(2)6-9-3-4-10-11(5-9)15-7-14-10/h3-5H,6-7H2,1-2H3
Chemical Name	N-(1,3-benzodioxol-5-ylmethyl)-N-methylacetamide
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	Human Endogenous Metabolite
ln Vitro	SY-640 reduces the quantity of cells that invade the liver and lessens the elevation in leukocyte function-associated antigen-1 expression on these cells[1].
ln Vivo	Although a single dosage has little impact, SY-640 (oral; 150 mg/kg; once daily for 7 days) effectively reduces liver injury produced by lipopolysaccharide and Propionibacterium acnes[1]. In mice, SY-640 (po; 150 mg/kg; once daily for three days) dramatically raises the amount of liver microsomal cytochrome P-450 and the activity of aminopyrine demethylase. Two hours after oral SY-640 treatment, there is a clear inhibition of the hepatic microsomal aminopyrine demethylase activity[2].
References	[1]. Hepatoprotective effect of SY-640, a novel acetamide derivative, on Propionibacterium acnes and lipopolysaccharide-induced liver injury in mice. Arch Int Pharmacodyn Ther. Mar-Apr 1995;329(2):319-30. [2]. [Inhibitory effect of 2-(N-acetyl-methyl amino)-3',4'-methylenedioxyacetyl-aminophene(SY-640) on covalent binding of carcinogenic benzo(a)pyrene with mouse hepatocyte nuclear DNA]. Yao Xue Xue Bao. 1997 Sep;32(9):663-8.

Solubility Data

Solubility (In Vitro)

DMSO: 100 mg/mL (482.56 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (12.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	4.8256 mL	24.1278 mL	48.2556 mL
	5 mM	0.9651 mL	4.8256 mL	9.6511 mL
	10 mM	0.4826 mL	2.4128 mL	4.8256 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.